Skip to main content

Table 2 Demographics and baseline characteristics

From: A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT

 

Idursulfase-IT

(n = 34)

No idursulfase-IT

(n = 15)

Overall

(N = 49)

Age, years

Mean (SD)

5.0 (1.5)

5.3 (2.6)

5.1 (1.9)

Median (range)

4.6 (3.1, 8.7)

4.8 (3.1, 13.0)

4.6 (3.1, 13.0)

Patients by age group, n (%)

Aged < 6 years

28 (82.4)

12 (80.0)

40 (81.6)

Aged ≥ 6 years

6 (17.6)

3 (20.0)

9 (18.4)

Race, n (%)

White

23 (67.6)

12 (80.0)

35 (71.4)

Asian

4 (11.8)

0

4 (8.2)

Black or African American

1 (2.9)

0

1 (2.0)

Other

6 (17.6)

3 (20.0)

9 (18.4)

Height, cm

Mean (SD)

111.7 (9.5)

110.9 (11.9)

111.5 (10.2)

108.8 (93.0, 140.0)

Median (range)

109.4 (95.7, 140.0)

107.9 (93.0, 137.7)

Weight, kg

Mean (SD)

24.5 (4.9)

25.3 (8.4)

24.8 (6.1)

Median (range)

23.8 (18.5, 39.8)

23.3 (17.0, 48.4)

23.6 (17.0, 48.4)

Baseline DAS-II GCA score

Mean (SD)

68.4 (8.3)

67.3 (7.5)

68.0 (8.0)

Median (range)

67.5 (55, 85)

66.0 (56, 78)

67.0 (55, 85)

Patients by baseline DAS-II GCA score category, n (%)

DAS-II GCA score ≤ 70

20 (58.8)

9 (60.0)

29 (59.2)

DAS-II GCA score > 70

14 (41.2)

6 (40.0)

20 (40.8)

Patients by type of IDS variant, n (%)

Missense

17 (50.0)

7 (46.7)

24 (49.0)

Frameshift

5 (14.7)

3 (20.0)

8 (16.3)

Large deletion or complete deletion/large rearrangement

5 (14.7)

0

5 (10.2)

Intronic

2 (5.9)

2 (13.3)

4 (8.2)

Nonsense

3 (8.8)

1 (6.7)

4 (8.2)

Splice site

1 (2.9)

0

1 (2.0)

Unclassifiable

1 (2.9)

2 (13.3)

3 (6.1)

  1. DAS-II Differential Ability Scales, Second Edition; GCA General Conceptual Ability; IDS, iduronate-2-sulfatase gene; IT intrathecal; SD standard deviation